Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (25) 25
index medicus (23) 23
male (12) 12
female (11) 11
aged (9) 9
multiple myeloma (9) 9
multiple myeloma - drug therapy (9) 9
oncology (9) 9
hematology, oncology and palliative medicine (8) 8
middle aged (7) 7
adult (6) 6
analysis (6) 6
cancer (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
bortezomib (5) 5
chemotherapy (5) 5
dexamethasone (5) 5
drug administration schedule (5) 5
gene expression (5) 5
proteins (5) 5
transplants & implants (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
biochemistry & molecular biology (4) 4
care and treatment (4) 4
dexamethasone - administration & dosage (4) 4
dna (4) 4
history (4) 4
medicine (4) 4
melphalan (4) 4
prednisone (4) 4
studies (4) 4
thalidomide - administration & dosage (4) 4
therapy (4) 4
treatment outcome (4) 4
antineoplastic agents - chemistry (3) 3
antineoplastic agents - pharmacology (3) 3
bone marrow (3) 3
cell line, tumor (3) 3
clinical trials (3) 3
deoxyribonucleic acid--dna (3) 3
disease-free survival (3) 3
dosage and administration (3) 3
drug therapy (3) 3
elderly-patients (3) 3
genomes (3) 3
hematology (3) 3
internal medicine (3) 3
leukemia (3) 3
life sciences (3) 3
medicine & public health (3) 3
medicine, general & internal (3) 3
multidisciplinary sciences (3) 3
multiple myeloma - diagnosis (3) 3
multiple myeloma - mortality (3) 3
patients (3) 3
peripheral neuropathy (3) 3
prognosis (3) 3
prostate cancer (3) 3
research article (3) 3
safety (3) 3
stem-cell transplantation (3) 3
survival (3) 3
thalidomide (3) 3
thalidomide - adverse effects (3) 3
thalidomide - analogs & derivatives (3) 3
toxicity (3) 3
abridged index medicus (2) 2
adolescent (2) 2
adsorption (2) 2
alanine - chemistry (2) 2
alanine - pharmacology (2) 2
amino acids (2) 2
analytical chemistry (2) 2
animals (2) 2
antihypertensive agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols (2) 2
antitumor-activity (2) 2
biochemical engineering (2) 2
biochemistry, general (2) 2
biomarkers (2) 2
biosensors (2) 2
boronic acids - adverse effects (2) 2
breast-cancer (2) 2
cell proliferation - drug effects (2) 2
combination (2) 2
cyclophosphamide (2) 2
deoxyribonucleic acid (2) 2
design (2) 2
development and progression (2) 2
devices (2) 2
dexamethasone - adverse effects (2) 2
diagnosis (2) 2
dogs (2) 2
efficacy (2) 2
electronic books (2) 2
elektrisches signal (2) 2
elektrizitätstransport (2) 2
eumelanin (2) 2
field-effect transistors (2) 2
films (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
by Kumar, Shaji, Prof and Paiva, Bruno, PhD and Anderson, Kenneth C, Prof and Durie, Brian, Prof and Landgren, Ola, MD and Moreau, Philippe, Prof and Munshi, Nikhil, Prof and Lonial, Sagar, MD and Bladé, Joan, Prof and Mateos, Maria-Victoria, Prof and Dimopoulos, Meletios, Prof MD and Kastritis, Efstathios, MD and Boccadoro, Mario, Prof and Orlowski, Robert, Prof and Goldschmidt, Hartmut, Prof and Spencer, Andrew, Prof and Hou, Jian, Prof and Chng, Wee Joo, Prof and Usmani, Saad Z, MD and Zamagni, Elena, MD and Shimizu, Kazuyuki, Prof and Jagannath, Sundar, Prof and Johnsen, Hans E, Prof and Terpos, Evangelos, MD and Reiman, Anthony, Prof and Kyle, Robert A, Prof and Sonneveld, Pieter, Prof and Richardson, Paul G, Prof and McCarthy, Philip, Prof and Ludwig, Heinz, Prof and Chen, Wenming, Prof and Cavo, Michele, Prof and Harousseau, Jean-Luc, Prof and Lentzsch, Suzanne, Prof and Hillengass, Jens, MD and Palumbo, Antonio, Prof and Orfao, Alberto, Prof and Rajkumar, S Vincent, Prof and Miguel, Jesus San, Prof and Avet-Loiseau, Herve, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Summary Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have... 
Hematology, Oncology and Palliative Medicine | WHOLE-BODY MRI | FREE LIGHT-CHAIN | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | MULTIPARAMETER FLOW-CYTOMETRY | CIRCULATING PLASMA-CELLS | BONE-MARROW | EXTRAMEDULLARY DISEASE | HIGH-DOSE CHEMOTHERAPY | TIME QUANTITATIVE PCR | STEM-CELL TRANSPLANTATION | Multiple Myeloma - drug therapy | Practice Guidelines as Topic - standards | Humans | Neoplasm, Residual - diagnosis | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm, Residual - chemically induced | Consensus | Multiple myeloma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
by Dimopoulos, Meletios A, Prof and Moreau, Philippe, Prof and Palumbo, Antonio, Prof and Joshua, Douglas, Prof and Pour, Ludek, Prof and Hájek, Roman, Prof and Facon, Thierry, Prof and Ludwig, Heinz, Prof and Oriol, Albert, Prof and Goldschmidt, Hartmut, Prof and Rosiñol, Laura, Prof and Straub, Jan, Prof and Suvorov, Aleksandr, Prof and Araujo, Carla, Prof and Rimashevskaya, Elena, Prof and Pika, Tomas, Prof and Gaidano, Gianluca, Prof and Weisel, Katja, Prof and Goranova-Marinova, Vesselina, Prof and Schwarer, Anthony, Prof and Minuk, Leonard, Prof and Masszi, Tamás, Prof and Karamanesht, Ievgenii, Prof and Offidani, Massimo, Prof and Hungria, Vania, Prof and Spencer, Andrew, Prof and Orlowski, Robert Z, MD and Gillenwater, Heidi H, MD and Mohamed, Nehal, PhD and Feng, Shibao, PhD and Chng, Wee-Joo, Prof and ENDEAVOR Investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Summary Background Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | END-POINTS | ONCOLOGY | SAFETY | Dexamethasone - administration & dosage | Follow-Up Studies | Humans | Anemia - chemically induced | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Survival Rate | Thrombocytopenia - chemically induced | Oligopeptides - adverse effects | Disease-Free Survival | Retreatment | Multiple Myeloma - drug therapy | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pneumonia - chemically induced | Hypertension - chemically induced | Bortezomib - adverse effects | Female | Aged | Oligopeptides - administration & dosage | Care and treatment | Relapse | Dexamethasone | Bortezomib | Multiple myeloma | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
by Rajkumar, S Vincent, Prof and Dimopoulos, Meletios A, Prof and Palumbo, Antonio, Prof and Blade, Joan, Md and Merlini, Giampaolo, Prof MD and Mateos, María-Victoria, MD and Kumar, Shaji, Prof and Hillengass, Jens, MD and Kastritis, Efstathios, MD and Richardson, Paul, Prof and Landgren, Ola, MD and Paiva, Bruno, MD and Dispenzieri, Angela, Prof and Weiss, Brendan, MD and LeLeu, Xavier, MD and Zweegman, Sonja, Prof and Lonial, Sagar, Prof and Rosinol, Laura, MD and Zamagni, Elena, MD and Jagannath, Sundar, Prof and Sezer, Orhan, Prof and Kristinsson, Sigurdur Y, MD and Caers, Jo, MD and Usmani, Saad Z, MD and Lahuerta, Juan José, MD and Johnsen, Hans Erik, Prof and Beksac, Meral, Prof and Cavo, Michele, Prof and Goldschmidt, Hartmut, Prof and Terpos, Evangelos, MD and Kyle, Robert A, Prof and Anderson, Kenneth C, Prof and Durie, Brian G M, Prof and Miguel, Jesus F San, Prof
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Summary This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to... 
Hematology, Oncology and Palliative Medicine | LIGHT-CHAIN RATIO | MARROW PLASMA-CELLS | IMAGING TECHNIQUES | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | MULTIPARAMETER FLOW-CYTOMETRY | LENALIDOMIDE PLUS DEXAMETHASONE | MONOCLONAL GAMMOPATHY | EARLY TREATMENT STRATEGIES | UNDETERMINED SIGNIFICANCE MGUS | INDEPENDENT RISK-FACTOR | Multiple Myeloma - pathology | Prognosis | Renal Insufficiency - diagnosis | Multiple Myeloma - diagnosis | Renal Insufficiency - pathology | Humans | Bone Marrow Cells - pathology | Renal Insufficiency - complications | Biomarkers, Tumor | Multiple myeloma | Diagnosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
by Palumbo, Antonio, Prof Dr and Bringhen, Sara, MD and Kumar, Shaji K, MD and Lupparelli, Giulia, BS and Usmani, Saad, MD and Waage, Anders, Prof and Larocca, Alessandra, MD and van der Holt, Bronno, PhD and Musto, Pellegrino, MD and Offidani, Massimo, MD and Petrucci, Maria T, MD and Evangelista, Andrea, MS and Zweegman, Sonja, MD and Nooka, Ajay K, MD and Spencer, Andrew, Prof and Dimopoulos, Meletios A, Prof and Hajek, Roman, MD and Cavo, Michele, Prof and Richardson, Paul, Prof and Lonial, Sagar, Prof and Ciccone, Giovannino, MD and Boccadoro, Mario, Prof and Anderson, Kenneth, MD and Barlogie, Bart, Prof and Sonneveld, Pieter, Prof and McCarthy, Philip L, Prof
Lancet Oncology, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 333 - 342
Summary Background Lenalidomide has been linked to second primary malignancies in myeloma. We aimed to pool and analyse available data to compare the incidence... 
Hematology, Oncology and Palliative Medicine | MULTIPLE-MYELOMA | SURVIVAL | ONCOLOGY | CYCLOPHOSPHAMIDE | SECONDARY | COMPETING RISKS | LEUKEMIA | STEM-CELL TRANSPLANTATION | MYELODYSPLASTIC SYNDROME | MELPHALAN | Thalidomide - adverse effects | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Melphalan - adverse effects | Neoplasms, Second Primary - chemically induced | Humans | Angiogenesis Inhibitors - adverse effects | Care and treatment | Analysis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
by Delforge, Michel, Prof and Bladé, Joan, Prof and Dimopoulos, Meletios A, Prof and Facon, Thierry, Prof and Kropff, Martin, MD and Ludwig, Heinz, Prof and Palumbo, Antonio, Prof and Van Damme, Philip, MD and San-Miguel, Jesús F, Prof and Sonneveld, Pieter, Prof
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1086 - 1095
Summary Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has substantially improved outcomes for... 
Hematology, Oncology and Palliative Medicine | SENSORY NEUROTOXICITY | PREDNISONE | THERAPY | ONCOLOGY | LENALIDOMIDE PLUS DEXAMETHASONE | THALIDOMIDE NEUROPATHY | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ANTITUMOR-ACTIVITY | ELDERLY-PATIENTS | CHEMOTHERAPY | Peripheral Nervous System Diseases - diagnosis | Peripheral Nervous System Diseases - epidemiology | Thalidomide - adverse effects | Peripheral Nervous System Diseases - chemically induced | Bortezomib | Risk Assessment | Humans | Risk Factors | Boronic Acids - adverse effects | Treatment Outcome | Incidence | Multiple Myeloma - drug therapy | Peripheral Nervous System Diseases - prevention & control | Antineoplastic Agents - adverse effects | Pyrazines - adverse effects | Multiple myeloma | Drugs | Side effects | Reviews | Immunomodulation | Toxicity | proteasome inhibitors | Peripheral neuropathy | Thalidomide | Quality of life
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
by Amorim, Sandy, MD and Stathis, Anastasios, MD and Gleeson, Mary, FRCPath and Iyengar, Sunil, MD and Magarotto, Valeria, MD and Leleu, Xavier, Prof and Morschhauser, Franck, Prof and Karlin, Lionel, MD and Broussais, Florence, MD and Rezai, Keyvan, ScD and Herait, Patrice, MD and Kahatt, Carmen, MD and Lokiec, François, PhD and Salles, Gilles, Prof and Facon, Thierry, Prof and Palumbo, Antonio, Prof and Cunningham, David, Prof and Zucca, Emanuele, MD and Thieblemont, Catherine, Prof
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 4, pp. e196 - e204
Summary Background The first-in-class small molecule inhibitor OTX015 (MK-8628) specifically binds to bromodomain motifs BRD2, BRD3, and BRD4 of bromodomain... 
Hematology, Oncology and Palliative Medicine | SELECTIVE-INHIBITION | BET | B-CELL LYMPHOMA | RESPONSE CRITERIA | C-MYC | BCL2 | HEMATOLOGY | IMMUNOHISTOCHEMISTRY | Acetanilides - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Male | United Kingdom | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Switzerland | Lymphoma - drug therapy | Maximum Tolerated Dose | Multiple Myeloma - drug therapy | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - therapeutic use | Acetanilides - therapeutic use | Female | Italy | Aged | France | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Classification and Data Mining
by Giusti, Antonio and Ritter, Gunter and Vichi, Maurizio
2013, 1. Aufl., Studies in classification, data analysis, and knowledge organization, ISBN 3642288936, 290
This volume contains both methodological papers showing new original methods, and papers on applications illustrating how new domain-specific knowledge can be... 
Data mining | Mathematics
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
by Cavo, Michele, Prof and Tacchetti, Paola, MD and Patriarca, Francesca, MD and Petrucci, Maria Teresa, MD and Pantani, Lucia, MD and Galli, Monica, MD and Di Raimondo, Francesco, Prof and Crippa, Claudia, MD and Zamagni, Elena, MD and Palumbo, Antonio, MD and Offidani, Massimo, MD and Corradini, Paolo, Prof and Narni, Franco, MD and Spadano, Antonio, MD and Pescosta, Norbert, MD and Deliliers, Giorgio Lambertenghi, Prof and Ledda, Antonio, MD and Cellini, Claudia, MD and Caravita, Tommaso, MD and Tosi, Patrizia, MD and Baccarani, Michele, Prof and GIMEMA Italian Myeloma Network
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Summary Background Thalidomide plus dexamethasone (TD) is a standard induction therapy for myeloma. We aimed to assess the efficacy and safety of addition of... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | PREDNISONE | CLINICAL-TRIAL | COMBINATION THERAPY | HERPES-ZOSTER | VTD | HIGH-DOSE MELPHALAN | ELDERLY-PATIENTS | III TRIAL | CHEMOTHERAPY | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Multiple Myeloma - drug therapy | Adult | Female | Boronic Acids - administration & dosage | Chemotherapy, Adjuvant | Multiple Myeloma - surgery | Thalidomide - adverse effects | Reoperation | Bortezomib | Dexamethasone - administration & dosage | Drug Administration Schedule | Multiple Myeloma - diagnosis | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Thalidomide - administration & dosage | Remission Induction | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - methods | Pyrazines - adverse effects | Italy | Aged | Complications and side effects | Dexamethasone | Multiple myeloma | Dosage and administration | Drug therapy | Thalidomide | Studies | Heart failure | Consolidation | Heart attacks | Data collection | Clinical medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
by Dimopoulos, Meletios A and Dimopoulos, Athanasios and Gay, Francesca and Schjesvold, Fredrik and Beksac, Meral and Hajek, Roman and Weisel, Katja Christina and Weisel, Katja and Goldschmidt, Hartmut and Maisnar, Vladimir and Moreau, Philippe and Min, Chang Ki and Pluta, Andrzej and Pluta, Agnieszka and Chng, Wee Joo and Chng, Wee-Joo and Kaiser, Martin and Zweegman, Sonja and Mateos, Maria-Victoria and Mateos, Maria Victoria and Spencer, Andrew and Iida, Shinsuke and Morgan, Gareth and Suryanarayan, Kaveri and Teng, Zhaoyang and Skacel, Tomas and Palumbo, Antonio and Dash, Ajeeta B and Gupta, Neeraj and Labotka, Richard and Rajkumar, S Vincent and Bar, Daniel and Basso, Alfredo and Fantl, Dorotea and He, Simon and Horvath, Neomi and Lee, Cindy and Lee, Jae Hoon and Rowlings, Phillip and Taylor, Kerry and Cochrane, Tara and Kwok, Fiona and Ramanathan, Sundreswran and Agis, Hermine and Zojer, Niklas and Kentos, Alain and Offner, Fritz and Van Droogenbroeck, Jan and Wu, Ka Lung and Maiolino, Angelo and Martinez, Gracia and Zanella, Karla and Capra, Marcelo and Araújo, Sérgio and Gregora, Evzen and Pour, Ludek and Scudla, Vlastimil and Spicka, Ivan and Abildgaard, Niels and Andersen, Niels and Jensen, Bo Amdi and Helleberg, Carsten and Plesner, Torben and Salomo, Morten and Svirskaite, Asta and Delarue, Richard and Blau, Igor and Schieferdecker, Aneta and Teleanu, Veronica and Munder, Markus and Röllig, Christoph and Salwender, Han-Juergen and Fuhrmann, Stephan and Duerig, Jan and Zeis, Matthias and Klein, Stefan and Reimer, Peter and Schmidt, Christian and Scheid, Christof and Mayer, Karin and Hoffmann, Martin and Sosada, Markus and Delimpasi, Sosana and Kyrtsonis, Mary-Christine and Anagnostopoulos, Achilleas and Nagy, Zsolt and Illés, Árpád and Egyed, Miklós and Borbényi, Zita and Mikala, Gabor and Dally, Najib and Horowitz, Netanel and Gutwein, Odit and Nemets, Anatoly and Vaxman, Iuliana and Shvetz, Olga and Trestman, Svetlana and Ruchlemer, Rosa and Nagler, Arnon and Tadmor, Tamar and ... and TOURMALINE-MM3 Study Grp and TOURMALINE-MM3 study group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 253 - 264
Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma.... 
DIAGNOSED MULTIPLE-MYELOMA | DEXAMETHASONE | HIGH-DOSE THERAPY | IMPROVES SURVIVAL | BORTEZOMIB | THALIDOMIDE | INDUCTION | LENALIDOMIDE MAINTENANCE | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | Therapy | Transplants & implants | Toxicity | Multiple myeloma | Medical services | Clinical trials | Stem cell transplantation | Transplantation | Peripheral neuropathy | Randomization | Motivation | Melphalan | Diagnosis | Safety | Drug dosages | Autografts | Cell survival | Hematology | Maintenance | Patients | Survival | Chemotherapy | Stem cells | Adults | Tourmaline | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights